Ironwood Pharmaceuticals (IRWD -4.5%) slides on a big Q1 miss this morning. Revenue dropped 73%...

Ironwood Pharmaceuticals (IRWD -4.5%) slides on a big Q1 miss this morning. Revenue dropped 73% Y/Y on weak sales of its IBS drug Linzess, while losses widened significantly as its bottom line was hit hard by a 92% rise in total costs - due largely to the rollout of Linzess - and an 11% jump in R&D expenses.